Trial Profile
Phase II, Multi-center, Open-Label, Single-Arm Study of Intratumoral Infusion of PRX321 in Subjects With Glioblastoma Multiforme at First Recurrence or Progression
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 May 2013
Price :
$35
*
At a glance
- Drugs Bizaxofusp (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms CLARITY-1
- 17 May 2012 Status changed from not yet recruiting to withdrawn prior to recruitment.
- 03 Dec 2008 New trial record.